Table 1.
Baseline characteristics.
| Variable | Data |
|---|---|
| Age (years) | 55 (45–63) |
| Gender | |
| Male | 184 (85.6) |
| Female | 31 (14.4) |
| Positive HBsAg | 167 (77.7) |
| Positive anti-HCV | 6 (2.8) |
| Cirrhosis | 148 (68.8) |
| Platelet count (109/L) | 164 (122–214) |
| Albumin (g/L) | 42.9 (39.2–45.3) |
| Total bilirubin (μmol/L) | 12.4 (8.8–16.2) |
| AST (U/L) | 36 (26–51) |
| Creatinine (μmol/L) | 79 (67–89) |
| Prothrombin time (sec) | 13.0 (12.3–14.0) |
| AFP (ng/mL) | |
| < 400 | 137 (63.7) |
| ≥ 400 | 78 (36.3) |
| CSPH | 41 (19.1) |
| Child–Pugh grade | |
| A | 206 (95.8) |
| B | 9 (4.2) |
| MELD score | 7.9 (7.1–8.9) |
| ALBI score | − 2.91 (− 3.19 to − 2.63) |
| FIB-4 index | 2.03 (1.43–3.40) |
| Tumor size (cm) | 6.0 (3.8–9.0) |
| Tumor number | |
| Single | 175 (81.4) |
| Multiple | 40 (18.6) |
| BCLC stage | |
| 0 and A | 135 (62.8) |
| B and C | 80 (37.2) |
| Extent of resection | |
| Minor | 166 (77.2) |
| Major | 49 (22.8) |
| Intraoperative blood loss (mL) | |
| > 400 | 145 (67.4) |
| ≤ 400 | 70 (32.6) |
| Intraoperative blood transfusion | 35 (16.3) |
Values were shown as n (%), or median (interquartile range).
AFP alphafoeto‐protein, ALBI albumin-bilirubin, AST aspartate aminotransferase, BCLC barcelona clinic liver cancer, CSPH clinically significant portal hypertension, FIB-4 fibrosis-4, HBsAg Hepatitis B surface antigen, HCV Hepatitis C virus, MELD model for end-stage liver disease.